They remain 16.6% down for the year but have likely been overlooked by many investors who were focusing on biotech this year.Ĭlayton believes the firm is well-positioned to benefit from advances in blood plasma therapies, with the stock a buy for balanced investors. Haemonetics’ shares have had a relatively pedestrian year, near-halving in the savage March sell-off before going on to claw back two-thirds of those losses.
Clayton said it is a fast-growing field and one in which the company has built a significant presence, operating in 16 different countries. “But a steady reopening of the economy and pent-up demand among holidaymakers to get out and travel ought to support earnings recovery in 2021,” he added, making it a good pick for balanced investors.īraintree, Massachusetts-based Haemonetics is a global operator in blood and plasma services and supplies.
Wilson added that he does not expect the airline conglomerate’s shares to return to their pre-pandemic levels next year, as “passenger travel levels are not seen returning to 2019 numbers for some years”. “In addition to the roll-out of vaccines, efforts by airlines like BA and airports like Heathrow to find creative solutions to ending quarantine requirements for travellers such as digital health passes will progress and make it easier for travel to take place,” he said. Wilson said that while the recent rebound has effectively priced in flight routes reopening in 2021, “there could be further upside driven by on the ground improvements to travel”. Since the November vaccine breakthroughs, IAG’s stock has surged by 80%, but remains 38.5% below where it started the year. Its stock was pummelled earlier in the year as flight routes, down just over 74% at their worst in August. With the requirement for extensive new housebuilding and infrastructure development in the U.S., he rates the stock a good play for more balanced investors.īritish Airways owner IAG is a classic reopening trade. “Vulcan sells building aggregates like gravel and because these are expensive to transport, Vulcan benefit from local monopolies and oligopolies, giving them reliable pricing power in what should be increasingly active markets,” However, Steve Clayton, head of equity funds at Hargreaves Lansdown, believes Vulcan is solidly positioned to prosper from the expected further financial stimulus under president-elect Joe Biden. Some analysts have highlighted the company’s hefty debt burden, at around three times earnings before interest, depreciation and tax as a red flag to investors. equities, still trading down 3.8% for the year. There are surely few markets as packed with potential as this one, as the UK prepares to launch its green industrial revolution and throw money at wind power, an area where Tekmar’s skills are likely to be in high demand,” he said.Īmerican building supplier Vulcan Materials has lagged the bounceback in U.S. “Meanwhile, the company’s leading position in the niche of protection systems for subsea cables and pipes offers plenty of scope for upside. Tekmar’s shares have sold off sharply in 2020, down 61.9%, in part down to contract delays that can punish small businesses disproportionately.īut Mould points to the company having net cash of £36 million -against a net asset value of £46 million- cost-cutting, and a new product launch due in 2021. micro-cap stock as high risk, given its size, but believes it can deliver for patient, longer-term investors. It’s a niche area, but fast-growing, with offshore wind projects a big customer.ĪJ Bell investment director Russ Mould describes the U.K.
Tekmar operates in power and telecommunications infrastructure, delivering systems that protect cables under the sea. However, “if there is a stock trading on this vaccine roll-out it’s Cineworld”, he cautioned. Assuming it can reopen its screens fully in May, it has sufficient cash to cover “2021 and beyond”.
0 kommentar(er)
